Neurocrine Biosciences, Inc.
Industry Group: Pharmaceuticals
Country/Region: United States of America
Identifier: NAS:NBIX
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.
ESG Risk Rating
Ranking
Industry Group (1st = lowest risk)
Pharmaceuticals 120 out of 850
Universe
Global Universe 5609 out of 15080
What are the ESG Risk Ratings?
Notice: The information is provided as is, for informational, non-commercial purposes only, does not constitute investment advice and is subject to conditions available in our Legal Disclaimer. They are not directed to, or intended for distribution to or use by India-based clients or users and their distribution to Indian resident individuals or entities is not permitted. Usage of this information is not permitted in any way, unless otherwise agreed in writing. By way of exception, usage of this information is permitted to the rated subject, limited to a single reference to the score on the rated subject’s sustainability webpage or CSR report, mentioning Sustainalytics as a source. For referencing Sustainalytics please consult the Company Guide.
Industry Comparison
| Company | ESG Risk Rating | Industry Rank |
|---|---|---|
| Neurocrine Biosciences, Inc. |
22
Medium
|
120 out of 850 |
| BioMarin Pharmaceutical, Inc. |
23.5
Medium
|
150 out of 850 |
| Insmed, Inc. |
25.7
Medium
|
235 out of 850 |
| Royalty Pharma Plc |
26.7
Medium
|
300 out of 850 |
| Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. |
29.9
Medium
|
486 out of 850 |
For corporate professionals interested in direct competitor insights
Sustainalytics' Peer Performance Insights gives an in-depth analysis of your company's ESG strengths and weaknesses compared to your competitors and industry performance. These insights can be used to identify areas of ESG improvement to help inform future management decisions that align with your organization's sustainability goals.
Our Approach to Calculating ESG Risk
The ESG Risk Ratings measure a company's exposure to industry-specific material ESG risks and how well a company is managing those risks.
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues. Our exposure score takes into consideration subindustry and company-specific factors such as its business model.
Management
Management refers to how well a company is managing its relevant ESG issues. Our management score assesses the robustness of a company's ESG programs, practices and policies.
How do the ESG Risk Ratings work?
Top Material ESG Issues for Neurocrine Biosciences, Inc.
Understand how exposed companies are to specific material ESG issues and how well companies are managing these issues.
What are Material ESG Issues?
Material ESG issues are issues that are considered to be financially material to a given company in a relevant sub-industry.
Controversy Rating
Highest Controversy level that has impacted Neurocrine Biosciences, Inc.'s ESG Risk Rating in the last three years
Highest Controversy Level
Contributing Events
Highest Controversy Events Locations
